Itamar Medical Ltd., a medical technology company, develops and commercializes non-invasive medical devices and solutions for the treatment of respiratory sleep disorders. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities. It provides WatchPAT device, which enable to conduct home sleep apnea tests for the treatment of sleep apnea, such as obstructive sleep apnea; EndoPAT device that diagnoses endothelial dysfunction; and Loop device, a wrist device for measuring and recording physiological parameters, such as SpO2, respiration rate, and heart rate. The company operates in the United States, Canada, Europe, Israel, Japan, rest of the Asia Pacific, and internationally. The company was formerly known as Itamar Medical (CM) 1997 Ltd. and changed its name to Itamar Medical Ltd. in July 2000. Itamar Medical Ltd. was incorporated in 1997 and is headquartered in Caesarea, Israel.
IPO Year: n/a
Exchange: NASDAQ
Website: itamar-medical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/20/2021 | $30.00 → $31.00 | Outperform → Market Perform | SVB Leerink |
| 9/15/2021 | $33.85 | Buy → Neutral | Ladenburg Thalmann |
| 9/14/2021 | $36.00 → $31.00 | Buy → Neutral | HC Wainwright & Co. |
| 9/14/2021 | $30.00 → $31.00 | Outperform → Market Perform | Cowen & Co. |
15-12B - Itamar Medical Ltd. (0001613170) (Filer)
EFFECT - Itamar Medical Ltd. (0001613170) (Filer)
EFFECT - Itamar Medical Ltd. (0001613170) (Filer)
POS AM - Itamar Medical Ltd. (0001613170) (Filer)
POS AM - Itamar Medical Ltd. (0001613170) (Filer)
S-8 POS - Itamar Medical Ltd. (0001613170) (Filer)
S-8 POS - Itamar Medical Ltd. (0001613170) (Filer)
25-NSE - Itamar Medical Ltd. (0001613170) (Subject)
6-K - Itamar Medical Ltd. (0001613170) (Filer)
6-K - Itamar Medical Ltd. (0001613170) (Filer)
- Revenues Increased 23% Year-over-Year to $13.6 Million - - U.S. WatchPAT™ Revenues Increased 27% Year-over-Year to $11.3 Million - CAESAREA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the third quarter of 2021. "Third quarter results represent the strong traction our WatchPAT™ platform technology has gained entering the second half of 2021. Growth in the U.S. continues to outpace our overall growth on top of expanding adoption in the markets we serve thr
- Revenues Increased 41% Year-over-Year to $12.6 Million - - U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million - - Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the second quarter of 2021. "Our second quarter results demonstrated further growth as our WatchPAT™ technol
CAESAREA, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report its financial results for the second quarter 2021 before the U.S. market opens on Tuesday, August 10, 2021. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update. The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO. To listen live via webcast, please visit https://edge.media-server.com/mm
SC 13G/A - Itamar Medical Ltd. (0001613170) (Subject)
SC 13G/A - Itamar Medical Ltd. (0001613170) (Subject)
SC 13G - Itamar Medical Ltd. (0001613170) (Subject)
SC 13G/A - Itamar Medical Ltd. (0001613170) (Subject)
SC 13G/A - Itamar Medical Ltd. (0001613170) (Subject)
SVB Leerink downgraded Itamar Medical from Outperform to Market Perform and set a new price target of $31.00 from $30.00 previously
Ladenburg Thalmann downgraded Itamar Medical from Buy to Neutral and set a new price target of $33.85
HC Wainwright & Co. downgraded Itamar Medical from Buy to Neutral and set a new price target of $31.00 from $36.00 previously
Cowen & Co. downgraded Itamar Medical from Outperform to Market Perform and set a new price target of $31.00 from $30.00 previously
SVB Leerink reiterated coverage of Itamar Medical with a rating of Outperform and set a new price target of $30.00 from $33.00 previously
HC Wainwright reiterated coverage of Itamar Medical with a rating of Buy and set a new price target of $36.00 from $30.00 previously
HC Wainwright & Co. reiterated coverage of Itamar Medical with a rating of Buy and set a new price target of $36.00 from $30.00 previously
Piper Sandler reiterated coverage of Itamar Medical with a rating of Overweight and set a new price target of $30.00 from $26.00 previously
- Revenues Increased 23% Year-over-Year to $13.6 Million - - U.S. WatchPAT™ Revenues Increased 27% Year-over-Year to $11.3 Million - CAESAREA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the third quarter of 2021. "Third quarter results represent the strong traction our WatchPAT™ platform technology has gained entering the second half of 2021. Growth in the U.S. continues to outpace our overall growth on top of expanding adoption in the markets we serve thr
CAESAREA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors. Ms. Ortigas-Wedekind brings more than 30 years of medical technology and digital health experience including leadership roles in commercial and strategic marketing. She is currently the Chief Commercial Strategy Officer for Fogarty Innovation, a nonprofit organization in the medical technology space. In this role she is responsible for delivering commercial strategy gu
- Revenues Increased 41% Year-over-Year to $12.6 Million - - U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million - - Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the second quarter of 2021. "Our second quarter results demonstrated further growth as our WatchPAT™ technol
CAESAREA, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report its financial results for the second quarter 2021 before the U.S. market opens on Tuesday, August 10, 2021. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update. The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO. To listen live via webcast, please visit https://edge.media-server.com/mm
CAESAREA, Israel, June 30, 2021 (GLOBE NEWSWIRE) -- ItamarTM Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the company will present at the upcoming Ladenburg Thalmann Annual Healthcare Conference. Itamar's management is scheduled to present on Wednesday, July 14, 2021 at 8:30 a.m. ET/ 5:30 a.m. PT. Interested parties may access a live and archived webcast of the presentation on the investor section of the Company's website at: www.itamar-medical.com. About Itamar Medical Ltd.Itamar Medical is a medical technology company focused on th
Enables Patient Smartphone App to Collect Subjective Data at Time of Test Designed to Improve the Quality and Efficiency of Home Sleep Diagnostics CAESAREA, Israel, June 07, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced two enhancements to its WatchPAT™ product line that the Company plans to unveil on June 11 during the Virtual SLEEP 2021 Conference, a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. “These product enhancements reflect our commitment to continuous i
CAESAREA, Israel, May 24, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Brad Fluegel to its Board of Directors. Mr. Fluegel's vast experience includes wide ranging leadership roles and 25+ years in the healthcare sector, primarily in strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for driving all commercial healthcare activities, including sales
– First Quarter 2021 Revenues Increase 43% to $12.0 Million – – U.S. WatchPAT™ Revenues Increase 38% to $8.4 Million – – Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT – CAESAREA, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the first quarter of 2021. "We were pleased to see the momentum from the second half of 2020 continue into new year, enabling us to achieve record first quarter revenue. Our U.S. core sleep business was once agai
CAESAREA, Israel, May 05, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report its financial results for the first quarter 2021 before the U.S. market opens on Wednesday, May 19, 2021. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update. The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO. To listen live via webcast, please visit https://edge.media-server.com/mmc/p
Significant Majority Expect Home Sleep Apnea Test Usage to Expand and in-lab Usage to Decline Most Clinicians Expect More than Half of Future Sleep Diagnostics Will Be At-Home Tests Results Indicate Vast Majority of Participants Use HSAT in Their Practices Today CAESAREA, Israel, April 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced results from a recent survey to health care professionals that covered sleep testing dynamics in their practices during 2020 and expectations for future use of Home Sleep Ap
CAESAREA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors. Ms. Ortigas-Wedekind brings more than 30 years of medical technology and digital health experience including leadership roles in commercial and strategic marketing. She is currently the Chief Commercial Strategy Officer for Fogarty Innovation, a nonprofit organization in the medical technology space. In this role she is responsible for delivering commercial strategy gu
CAESAREA, Israel, May 24, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Brad Fluegel to its Board of Directors. Mr. Fluegel's vast experience includes wide ranging leadership roles and 25+ years in the healthcare sector, primarily in strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for driving all commercial healthcare activities, including sales